Nektar sold less, spent more on research, and burned more cash.

The biotech’s six-month revenue fell 9.3% from the comparable period to $10.1 million, while research and development spending rose 30.9% to $39.1 million. Operating cash flow went from negative $94.8 million to negative $120.1 million. R&D spending rose as the revenue base got smaller, while operating cash flow worsened.

That makes the headline net loss a poor shortcut. Net loss narrowed slightly, from $41.6 million to $40.6 million, even as the operating loss widened from $36.2 million to $42.3 million. Diluted shares rose 134.6%, from 14.1 million to 33.1 million, and diluted loss per share moved from negative $2.95 to negative $1.23. The arithmetic improved per share largely because there were many more shares over which to spread the loss, not because the operating picture got easier.

Nektar’s cash balance fell 8.7% to $39.3 million. Capital spending was still small in absolute terms, at $112,000, while operating cash flow was negative $120.1 million. The company does not disclose a new financing in this filing.

Management describes the business as dependent on outcomes that are both expensive and outside the income statement’s neat little boxes:

"Our current business is subject to significant uncertainties and risks as a result of, among other factors, clinical and regulatory outcomes for rezpegaldesleukin, and our TNFR2 program, including NKTR-0165 and NKTR-0166; the sales levels for those products, if and when they are approved; whether, when and on what terms we are able to enter into new collaboration transactions; expenses being higher or timelines being longer than anticipated, unplanned expenses and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations;"

Nektar Therapeutics, 10-Q, August 14, 2026

In plain English, future revenue depends on drug development, approvals, sales, and collaboration deals. The current numbers show the spending side of that equation more clearly than the payoff side.

The timing risk is not theoretical in the filing. Nektar says trial costs can change with enrollment, the number of sites, study design, and health-authority requirements:

"The cost and time required to complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to: the number of patients required for a given clinical study design; the length of time required to enroll clinical study participants; the number and location of sites included in the clinical studies; the clinical study designs required by the health authorities (i.e. primary and secondary endpoints as well as the size of the study population needed to demonstrate efficacy and safety outcomes); the potential for changing standards of care for the target patient population;"

Nektar Therapeutics, 10-Q, August 14, 2026

That helps explain why higher R&D does not translate cleanly into a nearer revenue date. Nektar also said costs from its Phase 2b atopic dermatitis and alopecia areata studies fell as patients moved into maintenance or follow-up phases, partially offsetting other development spending. The portfolio can therefore contain both lower costs in completed trial stages and a larger overall research bill.

A related disclosure adds a specific collaboration wrinkle: Nektar has disclosed a dispute with Eli Lilly over its collaboration, alleging breach of contract and breach of the implied covenant of good faith. The relationship appears repeatedly in Nektar’s filings, but this filing does not quantify any resulting cash impact.

Nektar’s next 10-Q would put a sharper number on the tension by showing whether R&D spending and operating cash flow move again against revenue. Nektar’s R&D spending is higher while reported revenue is lower.

Source: Nektar Therapeutics 10-Qs filed August 14, 2026 and August 8, 2025.